MIM
COGT icon

MetLife Investment Management’s Cogent Biosciences COGT Stock Holding History

MetLife Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75M Buy
96,979
+18,358
+23% +$642K 0.02% 801
2026
Q1 		$3.03M Buy
78,621
+1,145
+1% +$42.3K 0.02% 841
2025
Q4 		$2.75M Buy
77,476
+1,775
+2% +$49.9K 0.01% 916
2025
Q3 		$1.09M Buy
75,701
+11,989
+19% +$142K 0.01% 1393
2025
Q2 		$457K Buy
63,712
+10,976
+21% +$60.8K ﹤0.01% 1720
2025
Q1 		$316K Sell
52,736
-4,014
-7% -$31.5K ﹤0.01% 1943
2024
Q4 		$443K Buy
56,750
+3,382
+6% +$33.7K ﹤0.01% 1867
2024
Q3 		$576K Hold
53,368
– – ﹤0.01% 1708
2024
Q2 		$450K Buy
53,368
+10,726
+25% +$81.4K ﹤0.01% 1780
2024
Q1 		$287K Sell
42,642
-213
-0.5% -$1.32K ﹤0.01% 1980
2023
Q4 		$252K Hold
42,855
– – ﹤0.01% 2103
2023
Q3 		$418K Buy
42,855
+7,620
+22% +$90.4K ﹤0.01% 1742
2023
Q2 		$417K Buy
35,235
+1,217
+4% +$14K ﹤0.01% 1817
2023
Q1 		$367K Hold
34,018
– – ﹤0.01% 1844
2022
Q4 		$393K Hold
34,018
– – ﹤0.01% 1799
2022
Q3 		$508K Buy
34,018
+10,628
+45% +$146K ﹤0.01% 1623
2022
Q2 		$211K Buy
23,390
+6,930
+42% +$47.3K ﹤0.01% 2284
2022
Q1 		$123K Buy
16,460
+12,193
+286% +$84.9K ﹤0.01% 2585
2021
Q4 		$36.6K Sell
4,267
-9,755
-70% -$84.8K ﹤0.01% 2473
2021
Q3 		$118K Buy
+14,022
New +$107K ﹤0.01% 2365

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MetLife Investment Management's COGT Position: Q2 2026 in Review

MetLife Investment Management increased its Cogent Biosciences (COGT) stake by 23% in Q2 2026, buying an estimated $642K and bringing the position to 96,979 shares worth $3.75M. The position accounts for 0.02% of the portfolio, ranked #801.

MetLife Investment Management first reported a position in COGT in Q3 2021 and has held it in 20 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • MetLife Investment Management held 96,979 shares of Cogent Biosciences worth $3.75M as of Q2 2026.
  • MetLife Investment Management bought 18,358 Cogent Biosciences shares in Q2 2026, an estimated $642K.
  • Cogent Biosciences made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #801 holding.
  • MetLife Investment Management first reported a position in Cogent Biosciences in Q3 2021 and has held it in 20 quarters since.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.